Form 4: Ligand Pharma Director Sells $1.7M in Shares

Ligand Pharmaceuticals Director Jason Aryeh sold 9,900 shares of common stock for approximately $1.7 million on September 23, 2025.

Summary

• Jason Aryeh, a Director of Ligand Pharmaceuticals Inc. (LGND), executed sales of common stock.
• A total of 9,900 shares were sold across three separate transactions on September 23, 2025.
• The sales generated approximately $1,708,900 in proceeds.
• The shares were sold at weighted-average prices ranging from $170.4051 to $171.9237 per share.
• Following these transactions, Mr. Aryeh directly beneficially owns 69,289 shares.
• Additionally, 51,594 shares are indirectly owned through funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates, and 5,025 shares are indirectly owned by a Trust.

Sentiment

Score: 4

Explanation: The sale of a significant number of shares by a director, even if pre-planned, generally carries a negative sentiment as it reduces insider ownership and can be interpreted as a lack of confidence in the company's near-term prospects or a belief that the stock is fully valued. However, it's not a complete divestment, and the remaining indirect holdings are substantial.

Negatives

• A director selling a significant number of shares may signal a lack of confidence in the company's near-term prospects or a belief that the stock is fully valued.
• The sale of 9,900 shares for approximately $1.7 million represents a notable divestment by a key insider.

Risks

• Increased market speculation regarding the company's future performance due to insider selling.
• Potential negative impact on investor sentiment, leading to downward pressure on the stock price.
• While the sale was executed under a Rule 10b5-1 plan, it still represents a reduction in insider ownership.

Future Outlook

The filing is a Form 4 detailing insider transactions and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider selling, particularly by a director, is often scrutinized by investors as it can be interpreted as a signal about the company's valuation or future prospects. While sales can be for personal liquidity reasons, a significant transaction like this may lead to questions about management's confidence, especially in the pharmaceutical industry where R&D milestones and regulatory approvals heavily influence stock performance.

Related Party Transactions

• Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP, which manage funds that indirectly own 51,594 shares of Ligand Pharmaceuticals common stock.
• These indirect holdings are subject to beneficial ownership rules under Section 16a-1.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Recommendation

While the sale of shares by a director is generally a negative signal, it's important to note that Jason Aryeh still retains significant direct and indirect beneficial ownership (over 125,000 shares). The transaction was also made pursuant to a Rule 10b5-1 plan, suggesting it was pre-scheduled rather than a reaction to immediate negative news. Investors should hold and monitor future insider activity and company performance, but exercise caution given the reduction in insider holdings.

Keywords

Ligand Pharmaceuticals, LGND, Insider Selling, Form 4, Director Stock Sale, Jason Aryeh, Equity Transaction, Beneficial Ownership